Anisodamine hydrobromide improves vertigo through the PI3K–Akt/NF–κB pathway Article Swipe
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1093/rpsppr/rqaf003
· OA: W4409870809
Objective Anisodamine hydrobromide (Ani HBr) is being considered as a potential treatment for vertigo. This study aims to investigate the preventive effect of Ani HBr on vertigo in guinea pigs and its relationship with the phosphoinositide 3-kinase (PI3K)–protein kinase B (Akt)/NF-κB pathway. Methods A vertigo model in guinea pigs was established by dripping chloroform into the external auditory canal. The vertigo model was evaluated using behavioral assessments, blood flow measurements, and auditory electrophysiology tests. Enzyme-linked immunosorbent assay (ELISA) and biochemical kits were used to detect inflammatory markers and oxidative stress markers. Additionally, western blot (WB) was performed to investigate the mechanisms of action of Ani HBr. Results Vertigo was characterized by behavioral abnormalities, reduced blood flow, and hearing impairment. However, Ani HBr alleviated these manifestations. Furthermore, Ani HBr significantly increased antioxidant capacity, reduced inflammation, and enhanced anti-inflammatory activity in a dose-dependent manner. WB analysis revealed that Ani HBr alleviated vertigo symptoms by activating the PI3K-Akt pathway and inhibiting the NF-κB pathway. Conclusions The results indicated that Ani HBr could alleviate vertigo symptoms in guinea pigs. Ani HBr activated the PI3K–Akt pathway and inhibited the NF-κB pathway, effectively reducing inflammatory response and cell apoptosis.
